Zacks Investment Research downgraded shares of Medicure Inc. (OTCMKTS:MCUJF) from a buy rating to a hold rating in a report issued on Tuesday morning.
According to Zacks, “Medicure Inc is a cardiovascular drug discovery and development company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine. In addition to MC-4232, they are also conducting Phase II clinical trials with MC-1, which is focused on the prevention and treatment of ischemia, ischemic reperfusion injury, and stroke. “
Separately, ValuEngine raised Medicure from a buy rating to a strong-buy rating in a report on Saturday, June 17th.
Shares of Medicure (MCUJF) opened at 6.55 on Tuesday. The firm has a 50-day moving average price of $6.30 and a 200-day moving average price of $6.21. The company has a market capitalization of $102.40 million, a PE ratio of 6.00 and a beta of 0.55. Medicure has a 12 month low of $4.11 and a 12 month high of $7.96.
Medicure Company Profile
Medicure Inc (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medicure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.